We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$1.39B
Cap. Flow %
-6.39%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Communication Services 8.41%
3 Technology 5.7%
4 Financials 3.99%
5 Consumer Discretionary 2.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
26
Twist Bioscience
TWST
$9.13B
$220M 1.01%
2,136,400
+708,750
+50% +$46.1M
AGIO icon
27
Agios Pharmaceuticals
AGIO
$1.98B
$220M 1.01%
5,917,400
+233,400
+4% +$7.08M
ARMK icon
28
Aramark
ARMK
$15.8B
$206M 0.95%
3,625,731
-2,509,700
-41% -$124M
BIDU icon
29
Baidu
BIDU
$31.6B
$138M 0.63%
1,203,785
+760,000
+171% +$94.1M
NVO
30
Novo Nordisk
NVO
$207B
$126M 0.58%
2,619,000
+1,837,000
+235% +$78.9M
ACHC icon
31
Acadia Healthcare
ACHC
$2.59B
$125M 0.58%
4,220,800
+2,484,000
+143% +$63.8M
BTSG icon
32
BrightSpring Health Services
BTSG
$11.6B
$121M 0.56%
1,732,800
+115,800
+7% +$6.43M
AZN icon
33
AstraZeneca
AZN
$257B
$109M 0.5%
574,000
+347,501
+153% +$65.4M
JNJ icon
34
Johnson & Johnson
JNJ
$651B
$104M 0.48%
408,000
+260,000
+176% +$60.6M
SOXX icon
35
PUT
iShares Semiconductor ETF
SOXX
$41.3B
$83.3M 0.38%
+130,000
New +$66M
PBLS
36
Parabilis Medicines Inc
PBLS
$4.86B
$64.8M 0.3%
+2,368,200
New +$65.4M
NVS icon
37
Novartis
NVS
$302B
$56.9M 0.26%
+363,000
New +$54.4M
GH icon
38
Guardant Health
GH
$22.9B
$48.3M 0.22%
322,200
+314,200
+3,928% +$34.2M
AVTX icon
39
Avalo Therapeutics
AVTX
$1.06B
$46.2M 0.21%
2,498,000
+1,582,000
+173% +$25M
JOYY
40
JOYY Inc
JOYY
$3.71B
$46.1M 0.21%
699,200
+121,000
+21% +$7.53M
ASMB icon
41
Assembly Biosciences
ASMB
$700M
$44.1M 0.2%
1,604,590
+377,000
+31% +$10.3M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$392M
$35.3M 0.16%
2,418,202
-453,660
-16% -$6.1M
MAZE
43
Maze Therapeutics
MAZE
$1.63B
$33.1M 0.15%
1,107,814
+734,814
+197% +$19.3M
CGON icon
44
CALL
CG Oncology
CGON
$7.07B
$28.4M 0.13%
400,000
+200,000
+100% +$13.1M
MRK icon
45
Merck
MRK
$376B
$25.6M 0.12%
199,000
-162,000
-45% -$19M
WRBY icon
46
Warby Parker
WRBY
$3.39B
$25.1M 0.12%
+828,000
New +$20.5M
PCSC
47
DELISTED
Perceptive Capital Solutions
PCSC
$24.5M 0.11%
2,250,000
– –
KLRA
48
Kailera Therapeutics
KLRA
$2.23B
$24.2M 0.11%
+1,100,000
New +$24.2M
RIO icon
49
Rio Tinto
RIO
$171B
$17.4M 0.08%
183,475
+129,675
+241% +$13.1M
AXTA icon
50
Axalta
AXTA
$7.75B
$16.4M 0.08%
+478,000
New +$14.4M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2026 Portfolio in Review

As of Q2 2026, Thomas Steyer held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Thomas Steyer withdrew a net $1.39B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Thomas Steyer's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Thomas Steyer added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Thomas Steyer's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Thomas Steyer fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Thomas Steyer's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Thomas Steyer opened 19 new positions and closed 105 in Q2 2026.
  • Thomas Steyer's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.